Milatuzumab
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].
Product Specifications
CAS Number
899796-83-9
Product Name Alternative
HLL1; MEDI-115
UNSPSC
12352203
Target
CD74
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/milatuzumab.html
Purity
99.39
Solubility
10 mM in DMSO
Smiles
[Milatuzumab]
Molecular Weight
(145.66 kDa)
References & Citations
[1]Alinari L, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117 (17) :4530-41.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
32494124 3x 1.0µg DNA
OLFM1 CRISPRa sgRNA lentivector (set of three targets)(Mouse)
Sign In for Pricing
View Details